STOCK TITAN

Jasper Therapeutics (JSPR) awards 7,500 stock options to board director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jasper Therapeutics director Lucas Svetlana received an automatic grant of stock options covering 7,500 shares of Voting Common Stock. The options were awarded under the Non-Employee Director Compensation Policy at an exercise price of $0.6300 per share, vesting in full on the first anniversary of the grant, and leave Lucas holding 7,500 derivative securities.

Positive

  • None.

Negative

  • None.
Insider Lucas Svetlana
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy F1 7,500 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy — 7,500 shares (Direct)
Footnotes (1)
  1. F1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Stock options granted 7,500 shares Stock Option (Right to Buy) awarded to director on 2026-07-31
Exercise price $0.6300 per share Conversion or exercise price of the granted stock options
Expiration date 2036-07-31 Expiration date of the stock option grant
Underlying Voting Common Stock 7,500 shares Number of Voting Common Stock shares underlying the option
Derivative holdings after grant 7,500 options Total derivative securities held following this award
Non-Employee Director Compensation Policy financial
"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy"
Stock Option (Right to Buy financial
"security_title: Stock Option (Right to Buy"
vesting financial
"which shall vest in full upon the first anniversary of the date of the grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price: 0.6300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did JSPR report for Lucas Svetlana?

Jasper Therapeutics reported that director Lucas Svetlana received a grant of 7,500 stock options. The options are for Voting Common Stock, were granted as director compensation, and increase Lucas’s derivative holdings to 7,500 options following the transaction.

How many Jasper Therapeutics (JSPR) shares are covered by the new stock options?

The stock option grant to Lucas Svetlana covers 7,500 shares of Jasper Therapeutics Voting Common Stock. Each option represents the right to buy one share, giving exposure to 7,500 shares if fully vested and exercised.

What is the exercise price of the stock options granted by JSPR?

The granted options have an exercise price of $0.6300 per share. This is the price at which Lucas Svetlana may purchase Jasper Therapeutics Voting Common Stock upon exercising the 7,500 stock options after they vest.

When do Lucas Svetlana’s JSPR director options vest?

The options granted to Lucas Svetlana vest in full on the first anniversary of the grant date. Vesting is conditioned on continued service as a director through that anniversary under the Non-Employee Director Compensation Policy.

Under what policy were the JSPR stock options granted to Lucas Svetlana?

The options were granted automatically under Jasper Therapeutics’ Non-Employee Director Compensation Policy. This policy provides that non-employee directors receive an option to purchase 7,500 shares on each annual stockholder meeting date, with full vesting after one year of service.

What are Lucas Svetlana’s Jasper Therapeutics derivative holdings after this Form 4?

Following the reported transaction, Lucas Svetlana holds 7,500 derivative securities in the form of stock options. These options relate to 7,500 shares of Voting Common Stock and reflect the entire derivative position shown in this report.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lucas Svetlana

(Last)(First)(Middle)
C/O JASPER THERAPEUTICS, INC.
2200 BRIDGE PKWY, SUITE #102

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy$0.6307/31/2026A7,50007/31/2027(1)07/31/2036(1)Voting Common Stock7,500$0.007,500D
Explanation of Responses:
1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
/s/ Herb Cross, as Attorney-in-Fact08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)